Dr. Susan Galbraith
Executive Vice-President, Oncology R&D


I lead Oncology R&D, early stage, and am responsible for research and early development from target selection to the initiation of pivotal trials.

I have over 20 years’ experience in drug discovery and development with a background as a Clinical Oncologist. I trained in medicine at Manchester and Cambridge Universities, was admitted to the Royal College of Physicians in 1992, and then trained in Clinical Oncology in London. I gained a Fellowship of the Royal College of Radiologists in 1997 and completed a PhD at the University of London involving translational work on a vascular-targeting agent. In 2017, I was awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research, and in 2018 I was admitted to the Fellowship of the Academy of Medical Sciences.

I moved from medicine to industry in 2001, to Bristol-Myers Squibb where I held increasing levels of responsibility becoming Vice President for the Clinical Discovery Oncology & Immunology and Clinical Biomarkers groups.

I joined AstraZeneca in 2010 as Head of Oncology in the IMED Biotech Unit. Since joining, four programmes have moved into Phase 3 trials; and two are now approved in many countries around the world.

For more information visit:  https://www.astrazeneca.com/our-company/leadership/susan-galbraith.html#!